STERIS stock reports 7.3 percent revenue growth as guidance holds

Published on 10/03/2026 at 23:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

STERIS stock posted adjusted EPS of USD 2.59 for fiscal Q1 2027, up 10.7 percent year over year. Fiscal 2027 adjusted EPS guidance stayed at USD 11.10-11.30.

Börsen-Editorialfoto mit Händlern vor Bildschirmen und steigenden Charts im Gesundheitssektor — Steris plc IE00BFY8C754 wird redaktionell am Börsenparkett der NYSE mit steigenden Healthcare-Sektor-Charts abgebildet, Illustration mit AI erstellt.

STERIS stock (ISIN IE00BFY8C754) was last at USD 208.54 on the NYSE on October 2, 2026, at 4:00 p.m. ET, down 0.38 percent from USD 209.34. The latest quarterly picture combines 7.3 percent revenue growth with reaffirmed fiscal 2027 adjusted EPS guidance of USD 11.10-11.30.

Revenue reaches USD 1.49 billion

According to Yahoo Finance on September 4, 2026, STERIS reported fiscal first-quarter 2027 revenue of USD 1.49 billion for the quarter ended June 30, 2026, up 7.3 percent year over year. Constant-currency organic revenue increased 6.2 percent, giving the headline growth a measurable operational base.

The same report showed adjusted EPS of USD 2.59, up 10.7 percent from USD 2.34 in the prior-year quarter, while GAAP EPS rose to USD 2.04 from USD 1.79. Adjusted EPS exceeded the consensus estimate by 1.97 percent, but revenue missed consensus by 0.83 percent, creating a mixed comparison beneath the stronger earnings figure.

Guidance keeps the earnings test clear

Yahoo Finance reported that STERIS reiterated fiscal 2027 as-reported revenue growth guidance of 7-8 percent and constant-currency organic growth guidance of 6-7 percent. Adjusted EPS guidance remained USD 11.10-11.30, so execution against the upper end is the key earnings checkpoint.

On October 3, 2026, MarketBeat reported that Wall Street Zen upgraded STERIS from buy to strong-buy. The article also cited a USD 271.33 average analyst target and a Moderate Buy consensus, while Piper Sandler had maintained an overweight rating with a USD 275.00 target on August 7, 2026.

Stock remains below its yearly high

At USD 208.54 on October 2, 2026, STERIS stood USD 60.90 below its 52-week high of USD 269.44 and USD 13.40 above its 52-week low of USD 195.14. Its market capitalization was USD 20.3 billion and trading volume was 675,312 shares on the same session.

The price action leaves the analyst target above the latest NYSE quote, while the operating data supply a concrete counterweight: revenue growth was positive, but the latest quarter also included a 0.83 percent revenue consensus miss. For investors, the next test is whether the 6-7 percent organic growth outlook converts into the guided adjusted EPS range.

STERIS stock carries a defined checkpoint

STERIS stock was last at USD 208.54 on the NYSE on October 2, 2026, at 4:00 p.m. ET. The combination of fiscal first-quarter adjusted EPS of USD 2.59, revenue of USD 1.49 billion and fiscal 2027 adjusted EPS guidance of USD 11.10-11.30 gives the shares a clear earnings framework rather than a single price signal.